<DOC>
	<DOCNO>NCT00068523</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy . Sometimes transplanted cell donor reject body 's normal cell . Ultraviolet-B light therapy give allogeneic stem cell transplantation may help prevent happen . PURPOSE : Clinical trial study effectiveness combine ultraviolet-B light therapy allogeneic stem cell transplantation treat patient hematologic malignancy .</brief_summary>
	<brief_title>Ultraviolet-B Light Therapy Allogeneic Stem Cell Transplantation Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety ultraviolet-B light therapy allogeneic peripheral blood stem cell transplantation patient hematologic malignancy demonstrate 100-day mortality great 15 % 1-year mortality great 40 % . - Determine frequency treatment-related toxicity lead death frequency disease relapse result death patient treat regimen . - Determine incidence severity acute chronic graft-versus-host disease patient treat regimen . Secondary - Determine rate donor allogeneic hematologic engraftment patient treat regimen . - Determine rate quality immune reconstitution peripheral blood composition immune cell skin transplantation patient . - Determine event-free overall survival patient treat regimen . OUTLINE : - Preparative regimen : Patients receive fludarabine IV 30 minute day -8 -4 cyclophosphamide IV 1 hour day -3 -2 . Patients also receive anti-thymocyte globulin IV 4 hour day -2 -1 . Patients undergo ultraviolet-B ( UVB ) light therapy every day day -10 -2 total 3 day . - Allogeneic peripheral blood stem cell ( PBSC ) transplantation : Patients undergo PBSC transplantation day 0 . - Graft-versus-host disease prophylaxis : Patients receive oral cyclosporine day -1 100 methylprednisolone ( oral IV ) day 5-15 . - Posttransplantation UVB light therapy : Following PBSC transplantation , patient undergo UVB light therapy twice weekly week 1 ( least 1 day apart ) three time weekly week 2-4 . Donor lymphocyte infusion perform per institutional guideline patient emerge donor chimerism post allogeneic PBSC transplantation progressing ( consistently 50 % first 3 month ) , donor chimerism recede ( 25 % ) despite cessation cyclosporine , relapse within 24 month allografting . Patients follow least monthly 3 month 6 , 12 , 18 , 24 month . PROJECTED ACCRUAL : A total 23-36 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis follow hematologic malignancy : Acute myeloid leukemia ( AML ) meeting follow criterion : First complete remission highrisk karyotype Translocations ( 15 ; 17 ) allow failed firstline induction therapy OR molecular evidence persistent disease exist Translocations ( 8 ; 21 ) inv ( 16 ) allow failed firstline induction therapy Second subsequent complete remission Minimal residual disease* Acute lymphoblastic leukemia meeting follow criterion : Failed induction therapy minimal residual disease* salvage therapy First complete remission highrisk karyotype ( e.g. , [ 4 ; 11 ] [ 9 ; 22 ] ) Relapsed disease allow provided second subsequent complete remission minimal residual disease* achieve Chronic myelogenous leukemia meeting follow criterion : Persistent relapse disease 1 year imatinib mesylate therapy Accelerated phase blast crisis Blast crisis allow reinduction chemotherapy place disease chronic phase Myelodysplastic syndrome meet follow criterion : Refractory medical management Cytogenetic abnormality predictive transformation acute leukemia , include 5q , 7q , monosomy 7 trisomy 8 , evidence evolution AML ( e.g. , refractory anemia excess blast ( RAEB ) RAEB transformation ) NonHodgkin 's lymphoma Hodgkin 's lymphoma meeting follow criterion : Beyond first complete remission fail primary induction therapy demonstrate sensitivity therapy 6 month transplantation Recurrent disease autologous stem cell transplantation Must least 3 month posttransplantation Cyclin D1+ mantle cell lymphoma allow induction therapy first remission Multiple myeloma meeting either follow criterion : Refractory relapse disease Residual disease autologous transplantation Chronic lymphocytic leukemia ( CLL ) meeting follow criterion : Peripheral blood absolute lymphocyte count great 5,000/mm^3 Small moderate size lymphocytes less 55 % prolymphocytes , atypical lymphocyte , lymphoblast morphologically Bcell Tcell Myeloproliferative disorder , include myelofibrosis Philadelphia negative Availability HLAA , B , DR identical family donor OR HLAA , B , DR genetically match unrelated donor Must meet 1 follow criterion : At least 55 year age time transplantation Received extensive prior therapy ( i.e. , 1 year alkylator therapy 2 different prior salvage regimen ) stem cell transplantation myeloablative conditioning ( either autologous allogeneic ) Presenting comorbid condition ( e.g. , abnormal cardiac , pulmonary , renal function and/or prior lifethreatening infection ) preclude eligibility enrollment allogeneic transplantation protocols full ablation condition No active CNS disease NOTE : *Defined circulate blast , absolute neutrophil count great 1,000/mm3 less 10 % blast bone marrow least 3 week last systemic chemotherapy PATIENT CHARACTERISTICS : Age See Disease Characteristics Over 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic See Disease Characteristics Hepatic Bilirubin great 2.0 mg/dL ALT/AST great 4 time normal Renal See Disease Characteristics Creatinine le 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular See Disease Characteristics Normal cardiac function echocardiogram radionuclide scan Shortening fraction ejection fraction least 40 % normal Pulmonary See Disease Characteristics DLCO least 60 % FEV_1 great 50 % predict Pulse oximetry great 85 % Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No uncontrolled active infection PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 2 week since prior biologic response modifier , signal transduction inhibitor , monoclonal antibody Chemotherapy See Disease Characteristics At least 4 week since prior systemic conventional chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Recovered prior therapy No concurrent sun block/sunscreen cosmetic may act sunscreen ( e.g. , lotion SPF ) day schedule ultravioletB light therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>